Denosumab
Osteoporosis
Phase 3Active
Key Facts
About Biocon
Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.
View full company profileTherapeutic Areas
Other Osteoporosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Teriparatide Injection | Amphastar Pharmaceuticals | Approved/Commercial |
| RT-102 | Rani Therapeutics | Phase 1 |
| EBP05 | Entera Bio | Preclinical |